Bristol-Myers Squibb and partner 2seventy bio are facing a delay in their attempt to bring BCMA-directed CAR-T therapy Abecma to the US market as an earlier-line therapy f
Antibody-drug conjugates (ADCs) took centre stage at the European Society of Medical Oncology (ESMO) Congress in Madrid 20th-24th October, which was back at full capac
CARGO Therapeutics has said it plans to offer around 18.8 million shares in the latest bid by a biotech to list on the Nasdaq, amid a desultory year for initial public off
CAR-T therapies have transformed the treatment of some haematological cancers, but haven’t made much headway for solid tumours – although BioNTech thinks it may have the k
A question which has long baffled scientists, frustrated clinicians, and devastated patients is why the immune system so effectively defends against infections, but so poorly deals with can
Last week, I had the privilege of heading into town in Boston to attend three days of the CAR-TCR conference, a major annual gathering of researchers and industry stakeholders concerned wit